https://www.selleckchem.com/products/BIBW2992.html
Improvement was defined as a ≥ 50% decrease in pain scale. Results Nineteen subjects completed the study and were used for analysis. The primary outcome changes in pain scale, 120 minutes after dose, showed a similar decrease for placebo and drug with a slightly wider 95% CI for placebo. Six subjects in each arm experienced a ≥ 50% decrease in pain scale. Conclusion These results support that timolol 0.5% ophthalmic solution is not an efficacious treatment for acute migraine headache. © 2020 The University of Kansas Medical Center.Auti
Like
Comment
Share
